clinical trial · NCT07760246
A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart
HealthyVerducatibMoxifloxacinPlacebo resembling VerducatibPlacebo resembling Moxifloxacin
brief summary
The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters
started
Aug 20, 2026
primary completion
Dec 30, 2026
completion
Dec 30, 2026
last updated
Nov 10, 2026
official title
A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group Design Trial With Moxifloxacin as Positive Control in a Nested Crossover to Evaluate the Effects of Multiple Doses of Verducatib (BI 1291583) on Cardiac Safety Parameters in Healthy Male and Female Trial Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol